Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
04:05pm, Tuesday, 07'th Sep 2021
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people batt
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2021 Results - Earnings Call Transcript
03:18am, Sunday, 08'th Aug 2021
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2021 Results - Earnings Call Transcript
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
10:39am, Thursday, 05'th Aug 2021
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -27.87% and -76.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
07:30am, Thursday, 05'th Aug 2021
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study
Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study
08:10am, Thursday, 03'rd Jun 2021
Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
04:52pm, Wednesday, 02'nd Jun 2021
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
08:30am, Friday, 28'th May 2021
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2021 Results - Earnings Call Transcript
01:19pm, Thursday, 13'th May 2021
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2021 Results - Earnings Call Transcript
Recap: WAVE Life Sciences Q1 Earnings
07:41am, Thursday, 13'th May 2021
Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimat
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
07:30am, Thursday, 13'th May 2021
Clinical trials underway with next-generation candidates incorporating PN chemistry
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
04:05pm, Monday, 10'th May 2021
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli
Here's Why Wave Life Sciences Crashed Today
02:04pm, Tuesday, 30'th Mar 2021
No one ever said drug development was easy.
WVE Stock Price Fell Over 20% Pre-Market: Why It Happened
07:39am, Tuesday, 30'th Mar 2021
The stock price of Wave Life Sciences Ltd (NASDAQ: WVE) fell by over 20% pre-market. This is why it happened.
Wave Life Sciences Stock Plunges After Antisense Oligonucleotide Candidates Disappoint In Huntington's Disease Study
05:38am, Tuesday, 30'th Mar 2021
Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. Wha
